https://www.nature.com/articles/s41586-023-06575-7
0
0
45 words
0
Comments
An orally bioavailable small-molecule active-site inhibitor of the phosphatases PTPN2 and PTPN1, ABBV-CLS-484, demonstrates immunotherapeutic efficacy in mouse models of cancer resistant to PD-1 blockade.
You are the first to view
Create an account or login to join the discussion